Envestnet Asset Management Inc. lowered its stake in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,783 shares of the company’s stock after selling 507 shares during the period. Envestnet Asset Management Inc.’s holdings in Enanta Pharmaceuticals were worth $294,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Great Point Partners LLC acquired a new stake in Enanta Pharmaceuticals during the third quarter valued at approximately $21,022,000. Matarin Capital Management LLC acquired a new stake in Enanta Pharmaceuticals during the third quarter valued at approximately $6,569,000. Candriam Luxembourg S.C.A. acquired a new stake in Enanta Pharmaceuticals during the third quarter valued at approximately $6,440,000. State Street Corp raised its stake in Enanta Pharmaceuticals by 71.5% in the fourth quarter. State Street Corp now owns 568,238 shares of the company’s stock valued at $19,036,000 after buying an additional 236,871 shares in the last quarter. Finally, Stonepine Capital Management LLC acquired a new stake in Enanta Pharmaceuticals during the fourth quarter valued at approximately $7,769,000. 71.61% of the stock is owned by institutional investors and hedge funds.
Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) opened at 30.80 on Friday. The stock’s 50 day moving average is $29.42 and its 200-day moving average is $29.17. The firm’s market cap is $586.46 million. Enanta Pharmaceuticals Inc has a 12-month low of $20.79 and a 12-month high of $37.31.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Wednesday, February 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by $0.08. The firm had revenue of $11.90 million for the quarter, compared to analyst estimates of $12.70 million. Enanta Pharmaceuticals had a negative return on equity of 3.54% and a negative net margin of 18.92%. The company’s revenue for the quarter was down 78.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.36 EPS.
Separately, Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 29th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $29.61.
In related news, insider Yat Sun Or sold 13,921 shares of the stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $35.09, for a total transaction of $488,487.89. Following the completion of the sale, the insider now owns 301,876 shares in the company, valued at approximately $10,592,828.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.28% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.